Why the US Attorney’s Office is Focused on Pharmaceutical Compliance (and what to do about it)
Part of our monthly series exploring the power of data and advanced analytics
With anti-bribery and corruption cases hitting a 2-Billion-dollar record high in 2019, and the FCPA Unit Chief, Charles Cain from the SEC Enforcement Division calling out Pharmaceutical sales as “a significant problem despite numerous prior enforcement actions,” the pressure is on the life sciences market to comply with federal regulations. From due diligence, creating an audit trail and understanding the top compliance barriers, you will learn how to apply this and more in your effort to build an advanced compliance screening strategy through the guidance and direction outlined in this report brought to you by LexisNexis® Risk Solutions in partnership with Fierce Pharma.
Prioritizing the steps you can take to avoid regulatory compliance complications, this report defines solutions that combine public and industry-specific content with advanced technology and analytics to assist our you in evaluating and predicting risk and enhancing operational efficiency.
With today’s rapidly evolving environment, we have created this five-part content series to highlight pressing issues and topics that are more pertinent today than ever before. Each month we will tackle a different issue — from trends to create successful life sciences organizations, to the importance of data analytics for business compliance — and we hope you use these as resources to glean insights that can be helpful for your organization.
By using the power of data and advanced analytics, we help our customers make better, timelier decisions.
Discover other pieces of this series by using #LNRSInnovations in the Search bar of this website.